Despite growing clinical support for use of TRK inhibitors1, integration of these drugs into public health systems presents significant challenges for health technology assessment (HTA) agencies who must consider the health economic impact of providing public access to TRK inhibitors in a setting of limited resources and growing cancer disease burden4. The gene discussed is NTRK1; the disease is cancer.